NSE
Natco Pharma LimitedNATCOPHARM
Natco Pharma Limited is an Indian pharmaceutical company focused on manufacturing and marketing of generic drugs.
| Key products | Generic medicines, APIs (Active Pharmaceutical Ingredients) |
|---|---|
| Geography | India, Export to Middle East, Africa, Europe |
| Competitors | Dr Reddy's Laboratories, Cipla Ltd |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Rs 1.50 Per Share
ex 2026-02-18
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ACUTAAS | +₹98.2 Cr | 1 | — | — | +4 | 6 |
| 2 | NATCOPHARMThis | +₹0 Cr | 2 | — | — | — | — |
| 3 | ACMESOLAR | — | — | — | — | +3 | 6 |
| 4 | AADHARHFC | — | — | — | — | — | — |
| 5 | AARTIIND | — | — | — | — | — | — |
| 6 | ACE | +₹0 Cr | 2 | — | — | — | — |
| 7 | AAVAS | −₹1.9 Cr | 2 | — | — | — | — |
| 8 | ABFRL | −₹142.6 Cr | 4 | — | — | — | — |
| 9 | ABLBL | −₹314.4 Cr | 29 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-02-18ActionInterim Dividend - Rs 1.50 Per ShareDividend
- 2025-11-26BulkBUY · ₹108.4 CrGRAVITON RESEARCH CAPITAL LLP
- 2025-11-26BulkSELL · ₹108.5 CrGRAVITON RESEARCH CAPITAL LLP
- 2025-11-26NetDay net −₹0.1 Cr
- 2025-11-20ActionInterim Dividend - Rs 1.50 Per ShareDividend
- 2025-08-19ActionInterim Dividend - Rs 2 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
No scored filings for NATCOPHARM yet.
2 deals · 2025-11-26 → 2025-11-26
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2025-11-26 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | BUY | ₹108.4 Cr |
| 2025-11-26 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | SELL | ₹108.5 Cr |
2 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on NATCOPHARM
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.